Journal for ImmunoTherapy of Cancer (Nov 2021)
312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90%
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Nov 2021)